Xilio Therapeutics, Inc.

XLO

Xilio Therapeutics, Inc.

XLO

Insider Sentiment (TTM):

Last Purchase:2026-03-26Last Sale:2026-01-02Shares Purchased (TTM):5,000Shares Sold (TTM):8,856

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,951,923Shares Outstanding:16,347,538Institutional Ownership Pct.:11.94%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	136	150	138	104	122	89	55	61	75	34	45	60
Assets Current
Assets Current	145	154	145	124	124	93	60	63	78	69	48	64
Receivables Net Current	-	-	-	-	-	-	-	-	-	30	-	-
Prepaid Expense And Other Assets Current	3	4	2	3	2	4	5	2	3	5	3	5
Restricted Cash Noncurrent	2	2	2	2	2	2	2	2	2	3	2	2
Property Plant And Equipment Net	3	4	4	4	4	4	4	5	5	6	6	6
Operating Lease Right Of Use Asset	4	4	4	4	4	4	5	5	5	5	5	5
Other Assets Noncurrent	-	-	-	-	-	-	-	-	0	0	0	0
Assets	154	163	155	134	134	104	71	75	90	83	61	78
Liabilities And Stockhold…
Accounts Payable Current	2	1	3	2	4	2	3	1	1	1	1	1
Accrued Liabilities Current	8	9	12	9	6	4	10	10	10	8	10	9
Deferred Revenue Current	23	32	40	44	42	40	14	26	27	22	-	-
Liabilities Current
Liabilities Current	34	43	56	56	53	48	27	38	39	32	16	17
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Notes Payable Current	-	-	-	-	-	-	-	-	-	-	3	5
Other Liabilities Current	-	-	-	-	-	-	-	-	0	0	0	0
Deferred Revenue Noncurrent	13	16	21	25	29	39	19	8	10	17	-	-
Operating Lease Liability Noncurrent	5	5	6	6	6	7	7	7	8	8	8	8
Warrants And Rights Outstanding	30	26	30	54	39	-	-	-	-	-	-	-
Liabilities	82	91	119	142	127	93	53	54	56	57	24	25
Common Stock Value	0	0	-	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	72	73	35	-8	7	11	18	21	33	26	37	52
Additional Paid In Capital	507	501	454	421	420	408	401	392	390	368	362	360
Retained Earnings Accumulated Deficit	-435	-428	-419	-429	-413	-397	-384	-371	-357	-343	-326	-308
Liabilities And Stockholders Equity	154	163	155	134	134	104	71	75	90	83	61	78
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	600	600	600	600	600	200	200	200	200	200	200	200
Common Stock Shares Issued	7	6	5	52	52	52	3	44	44	34	28	28
Shares Outstanding	7	6	5	52	52	52	3	44	44	34	28	28

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.39%	18.37%	17.46%	-	-	-	-	-	-	-	-	-
2025	48.61%	-6.25%	-3.19%	-0.43%	16.36%	13.37%	3.99%	-4.27%	-15.24%	9.03%	6.36%	5.73%
2024	-3.67%	-17.89%	-17.89%	-0.12%	-11.18%	10.59%	4.81%	-6.54%	-21.15%	-14.25%	-5.42%	34.93%
2023	-	-	-	-6.47%	-28.29%	-16.08%	-35.00%	-65.63%	-59.37%	-28.76%	-31.37%	-40.65%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.25	3.59	2.58	2.20	2.32	1.96	2.21	1.67	2.02	2.19	3.02	3.81
Quick Ratio	4.15	3.50	2.53	2.15	2.28	1.87	2.03	1.61	1.94	2.03	2.80	3.53
Working Capital	111.27M	111.25M	88.75M	67.69M	70.46M	45.56M	32.97M	25.29M	39.37M	37.60M	32.17M	47.55M
Leverage & Debt
Debt to Equity	1.13	1.25	3.39	-17.52	17.93	8.69	3.04	2.56	1.69	2.21	0.65	0.48
Debt Ratio	0.53	0.56	0.77	1.06	0.95	0.90	0.75	0.72	0.63	0.69	0.40	0.33
Efficiency & Turnover
Asset Turnover TTM	0.44	0.40	0.39	0.31	0.13	0.10	0.10	0.06	0.03	0.00	0.00	0.00
Receivables Turnover TTM	-	-	-	-	-	-	-	-	-	0.00	-	-
Per Share Metrics
Diluted EPS TTM	-1.12	-1.91	0.24	-0.41	-8.16	-10.18	0.40	-0.99	-1.13	-2.54	1.39	-2.95
Free Cash Flow Per Share TTM	-0.54	-3.51	-0.66	-0.32	-6.20	3.94	-4.82	-0.28	-0.30	-1.95	-2.52	-2.71
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-48.94%	-78.98%	-95.92%	-137.64%	-377.36%	-614.04%	-954.95%	-1,408.72%	-2,871.53%	-	-	-
Net Profit Margin TTM	-34.06%	-58.52%	-80.05%	-183.90%	-374.79%	-585.54%	-918.05%	-1,359.37%	-2,780.27%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	327.25%	476.71%	589.88%	588.40%	536.44%	-	-	-	-	-	-	-
Net Income Growth (1Y)	-61.17%	-42.36%	-39.84%	-6.87%	-14.21%	-23.47%	-23.77%	-22.67%	-22.22%	-20.73%	-13.40%	-35.19%
EPS Growth (1Y)	-86.22%	-81.19%	-72.49%	-58.98%	619.32%	300.32%	448.36%	-66.46%	-63.01%	-22.09%	-13.72%	-35.48%
Valuation Metrics
P/E TTM	-8.52	-4.39	-2.14	-29.08	-1.17	-1.00	-0.88	-11.15	-11.70	-5.95	-2.77	-10.01
P/B TTM	2.57	1.90	2.12	-210.10	9.28	5.05	2.90	33.38	22.94	16.38	5.75	15.49
P/S TTM	2.90	2.57	1.71	53.48	4.37	5.83	8.06	151.55	325.24	-	-	-
Market Cap	185.90M	137.48M	74.90M	1.70B	65.58M	54.08M	51.10M	700.15M	766.59M	422.04M	211.72M	813.05M
Enterprise Value	48.04M	-14.66M	-64.44M	1.60B	-57.76M	-34.99M	-4.19M	637.11M	689.88M	385.30M	170.33M	758.24M
Calculated Values
Free Cash Flow TTM	-10.49M	-57.37M	-5.51M	-46.54M	-42.72M	21.04M	-18.41M	-17.68M	-17.37M	-54.36M	-69.28M	-74.58M
Net Debt	-137.86M	-152.15M	-139.34M	-103.76M	-123.35M	-89.07M	-55.29M	-63.03M	-76.72M	-36.74M	-41.39M	-54.82M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-26Purchase

Owner: Shannon, James Samuel

Title: -

Shares: 5,000

Price/Share: $8.79

Value: $43,950.00

Shares Owned: 10,000

Relationship: Director

Ownership: Direct

2026-01-02Sale

Owner: Brennan, Kevin M.

Title: SVP, FINANCE AND ACCOUNTING

Shares: 1,826

Price/Share: $0.64

Value: $1,168.64

Shares Owned: 6,371

Relationship: Officer

Ownership: Direct

2026-01-02Sale

Owner: Frankenfield, Christopher…

Title: Chief Financial Officer

Shares: 7,030

Price/Share: $0.64

Value: $4,499.20

Shares Owned: 24,766

Relationship: Officer

Ownership: Direct

2025-06-17Purchase

Owner: Shannon, James Samuel

Title: -

Shares: 25,000

Price/Share: $0.69

Value: $17,250.00

Shares Owned: 70,000

Relationship: Director

Ownership: Direct

2025-06-16Purchase

Owner: Russo, Rene

Title: PRESIDENT AND CEO

Shares: 36,289

Price/Share: $0.68

Value: $24,676.52

Shares Owned: 281,172

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-26	Shannon, James Samuel	Director	-	Direct	Purchase	5,000	8.79	$43,950.00	10,000	4
2026-01-02	Brennan, Kevin M.	Officer	SVP, FINANCE AND ACCOUNTING	Direct	Sale	1,826	0.64	$1,168.64	6,371	4
2026-01-02	Frankenfield, Christopher…	Officer	Chief Financial Officer	Direct	Sale	7,030	0.64	$4,499.20	24,766	4
2025-06-17	Shannon, James Samuel	Director	-	Direct	Purchase	25,000	0.69	$17,250.00	70,000	4
2025-06-16	Russo, Rene	Director,Officer	PRESIDENT AND CEO	Direct	Purchase	36,289	0.68	$24,676.52	281,172	4
2025-01-02	Brennan, Kevin M.	Officer	SVP, FINANCE AND ACCOUNTING	Direct	Sale	1,803	0.98	$1,766.94	3,197	4
2025-01-02	Frankenfield, Christopher…	Officer	Chief Financial Officer	Direct	Sale	6,954	0.98	$6,814.92	12,421	4
2024-12-18	Gilead, Sciences, Inc.	TenPercentOwner	-	Direct	Purchase	1,759,978	1.04	$1,830,377.12	9,105,451	4
2024-04-02	Gilead, Sciences, Inc.	TenPercentOwner	-	Direct	Purchase	485,250	0.76	$368,790.00	7,345,473	4
2024-02-08	Atlas, Venture Fund Xi, L…	TenPercentOwner	-	Direct	Sale	733	0.64	$469.12	2,019,563	4
2024-01-12	Atlas, Venture Associates…	TenPercentOwner	-	Direct	Sale	1,540	0.83	$1,278.20	2,020,296	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

11.94%

Inst. Shares: 1,951,923

Shares Outstanding: 16,347,538

2025-12-31

Inst. Shares: 39,548,142

Shares Outstanding: 8,359,109

2025-09-30

15.29%

Inst. Shares: 22,027,204

Shares Outstanding: 144,106,869

2025-06-30

24.65%

Inst. Shares: 23,770,263

Shares Outstanding: 96,447,672

2025-03-31

Inst. Shares: 22,528,206

Shares Outstanding: 5,335,740

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,951,923	16,347,538	11.94%
2025-12-31	39,548,142	8,359,109	-
2025-09-30	22,027,204	144,106,869	15.29%
2025-06-30	23,770,263	96,447,672	24.65%
2025-03-31	22,528,206	5,335,740	-
2024-12-31	25,187,613	3,822,244	-
2024-09-30	14,477,824	63,465,063	22.81%
2024-06-30	13,033,700	57,760,178	22.57%
2024-03-31	10,719,378	27,912,584	38.40%
2023-12-31	14,281,368	27,496,107	51.94%
2023-09-30	14,974,638	27,523,821	54.41%
2023-06-30	15,116,813	27,468,668	55.03%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Xilio Therapeutics, Inc. (XLO) — SEC Financial Statements & Analysis

Xilio Therapeutics, Inc. (XLO) is a pharmaceutical preparations company, incorporated in DE. Xilio Therapeutics, Inc. trades on Nasdaq as: XLO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Xilio Therapeutics, Inc. reported a 327.25% year-over-year revenue growth, a Debt-to-Equity ratio of 1.13x, a Price-to-Sales (P/S) ratio of 2.90x (TTM), a Price-to-Book (P/B) ratio of 2.57x (TTM), at a market cap of $185.90M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 327.25%
Debt To Equity: 1.13x
P/S TTM: 2.90x
P/B TTM: 2.57x
Market Cap: $185.90M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Xilio Therapeutics, Inc. in?

Xilio Therapeutics, Inc. (XLO) operates in the Pharmaceutical Preparations industry.

What is XLO's market cap?

Xilio Therapeutics, Inc. (XLO) has a market capitalization of $185.90M as of 2026-06-30.

What exchange does XLO trade on?

Xilio Therapeutics, Inc. (XLO) trades on the Nasdaq.

Where is Xilio Therapeutics, Inc. incorporated?

Xilio Therapeutics, Inc. is incorporated in DE.